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Abstract
Objectives. To determine the mechanism of antimicrobial action of lactocin 160, a bacteriocin produced by the healthy
vaginal strain of Lactobacillus rhamnosus, using an established model, with Micrococcus luteus ATCC 10420 as a test organism.
Methods. Sensitivity of M. luteus to lactocin 160 was determined by the diffusion assay. Loss of cellular ATP in the lactocin-
treated cells was elucidated using a commercially available ATP determination kit (luciferin-luciferase bioluminescence
assay). Luminescence intensity as a reﬂection of ATP quantity was determined using a luminometer. Dissipation of
membrane potential (Dc) was studied using ﬂuorophore DiSC3(5) with the ﬂuorescence spectrum sensitive to changes in Dc.
Results. Lactocin 160 inhibited growth of M. luteus ATCC 10420 at a concentration of 5 mg/ml. There were no signiﬁcant
changes in the intracellular ATP level of M. luteus upon the addition of 20 mg/ml of lactocin 160. However, the extracellular
ATP level increased signiﬁcantly. This means that the treatment of cells with lactocin 160 resulted in an efﬂux of ATP from
inside the cells. Therefore, a partially puriﬁed lactocin 160 preparation (16 mg /ml of the bacteriocin in the sample) killed
sensitive cells and dissipated 3.12+0.36% of Dc.
Conclusion. Lactocin 160 has a mode of action typical for bacteriocins. It disturbs the cellular membrane (Dc dissipation)
and induces ATP efﬂux, most likely because of the pore formation, which is a common mechanism of action for many
bacteriocins.
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Introduction
Bacterial vaginosis (BV) is a vaginal, multi-microbial
syndrome that can be a risk factor for human
immunodeﬁciency virus (HIV) transmission and
acquisition. Several cross-sectional studies identify
BV as a cofactor in the sexual transmission of HIV
[1–3]. Major BV organisms directly up-regulate HIV
replication [4–6]. Our in vitro data indicated that the
most frequent BV-associated microorganisms Gard-
nerella vaginalis, Peptostreptococcus spp and Prevotella
bivia stimulate the expression of HIV [5,7].
Lactobacilli in the lower genital tract of healthy
females protect the vagina from the invasion of
pathogens by producing antimicrobial substances,
such as weak organic acids (mostly lactic acid),
bacteriocins and hydrogen peroxide [8–10]. Bacter-
iocins are deﬁned as proteinaceous substances that
exhibit antibacterial activity. Vaginal lactobacilli
produce bacteriocins effective against vaginal patho-
gens such as Enterococcus spp and Neisseria
gonorrhoeae [11], and may have a fungistatic effect
on Candida albicans [12]. Among 22 vaginal Lacto-
bacillus strains studied by Aroutcheva et al. [9,13],
77.3% exhibited antimicrobial activity against G.
vaginalis. One of these strains, designated Lactoba-
cillus rhamnosus 160, produces a bacteriocin named
lactocin 160 that inhibits growth of G. vaginalis [13].
Here we report for the ﬁrst time, our preliminary
data on the mechanism of antimicrobial action for
the bacteriocin produced by the vaginal strain of
Lactobacillus, lactocin 160, using a well-established
model where Micrococcus luteus ATCC 10420 is a test
organism [14].
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Lactocin 160 puriﬁcation
The bacteriocin producer L. rhamnosus 160 was
isolated from a patient with healthy vaginal micro-
ﬂora. Lactocin 160 was puriﬁed following the
previously described procedure [15]. Brieﬂy,
2000 ml of the overnight culture of L. rhamnosus
160 grown in MRS broth (Remel, KS) anaerobically
at 368C, were concentrated by centrifugation (7000 x
g, 20 min at 58C), washed three times in 1 6 PBS
(pH 6.0) and transferred into 200 ml of chemically
deﬁned media (CDM) composed from substances
found in vaginal secretion but without any proteins
and amino acids [16]. The cells were incubated
anaerobically at 378C for 18 h with constant shaking
and then removed by centrifugation at 12,000 x g for
25 min at 58C.
The non-lactocin 160 proteins were precipitated
from the CDM by 80% ammonium sulfate for 3 h at
58C. The precipitate was removed by centrifugation
at 12,000 x g for 25 min at 58C. The supernatant
containing lactocin 160 was dialyzed against deio-
nized water, using a dialysis bag with MW CO 500
(Spectrum, CA), within 3 days. The dialyzed
preparations were concentrated by lyophilization.
The 10–20% pre-cast sodium dodecyl sulfate
(SDS) polyacrilamide gel (Bio-Rad, CA) electro-
phoresis (SDS-PAGE) was conducted to determine
the presence of lactocin 160 in the sample. The SDS-
PAGE was conducted according to the Bio-Rad
manual at 200 V for 90 min. To visualize proteins,
the gel was stained with a Bio-Rad Silver Stain
according to the manufacturer’s instructions.
Nisin preparation
Nisin powder, puriﬁed bacteriocin produced by
Lactococcus lactis, was a gift from Aplin & Barrett
(Beaminster, UK). Nisin is the only lactic acid
bacteria-produced bacteriocin that is used for food
preservation in more than ﬁfty countries. Because it
is a class Ia bacteriocin from Lactococcus lactis, with a
well-studied mechanism of action, nisin was used as
a positive control [17].
A high concentration of nisin solution can only be
obtained at a low pH since this bacteriocin has the
best solubility in the pH range of 1.7–3.5. To prepare
a highly concentrated nisin stock solution, one gram
of dry preparation of the bacteriocin was dissolved in
1 ml of commonly used ‘‘nisin diluent’’ consisting of
0.02 N HCl (pH 1.7). The stock solution was used
to prepare working concentrations in the PBS buffer
(pH 7.2). Because of the high buffer capacity of the
PBS and the small amounts of nisin in ﬁnal
preparations, the pH of nisin working solutions was
approximately 7.0.
Well diffusion assay
The stock culture of Micrococcus luteus ATCC
10420 used in this study was stored in a nutrient
broth (Difco, MI) with 20% glycerol at 7708C.
The strain was streaked on a fresh nutrient agar
(Difco, MI) plate three times before it was used as
working culture, which was kept at 48C. The
CDM was used as a negative control. To conduct
the susceptibility test, a partially puriﬁed prepara-
tion of lactocin 160 was dissolved in PBS (pH 7.2)
at 20 mg/ml.
Before pouring plates, M. luteus ATCC 10420
cells were seeded into the nutrient agar to make a
ﬁnal concentration of approximately 10
4 CFU/ml.
When the agar was polymerized in the Petri dishes,
wells 6 mm in diameter were punctured in the agar.
Then 80 ml of the 2-fold dilutions of lactocin 160
preparation was added into the wells. The agar plates
were pre-incubated at 48C for 6 h, so the bacter-
iocins could diffuse into the agar, followed by 24 h of
incubation at 308C. The observed inhibition zones
indicated activity of the bacteriocins.
Protein assay
To determine protein (the bacteriocin) concentra-
tion in the partially puriﬁed preparation of lactocin
160, the RC DC
TM Protein Assay kit (BioRad) was
used according to the manufacturer’s manual.
ATP assay
First, an ATP standard curve was obtained by
following the procedure described in the manual
(Technical Bulletin No. BAAB-1) included with
the ATP bioluminescent assay kit (FL-AA, Sigma-
Aldrich Corporation, St. Louis, MO). The total
ATP level of both the normal and stressed cells
was determined as described previously [18].
Brieﬂy, 1 ml of M. luteus ATCC 10420 was
collected by centrifugation, and the pellet was re-
suspended in a 50 mM MES (2-[N-Morpholino]-
ethanesulfonic acid) buffer (pH 6.5) supplemented
with 0.2% glucose and 10 mM KCl to energize the
cells. The cell suspension was divided into 2
aliquots. One aliquot was treated with lactocin
160, and the other (no bacteriocin added) served
as the control. After 10 min of energization with
glucose, the 10 mg/ml (ﬁnal concentration) lacto-
cin 160 partially puriﬁed preparation was added in
one aliquot of cell suspension. At the same time,
the same volume of the MES buffer was added to
the control cells. For both cells with and without
lactocin 160 treatment, the procedures were the
same. To determine the total ATP level, at pre-
determined intervals, 20 ml of the cell suspension
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sulfoxide, Fischer Biotech, NJ) and mixed for
30 s before dilution with 4.9 ml of cold water
(48C). To measure the extracellular ATP level,
20 ml of the same cell suspension was mixed with
80 mlH 20 instead of DMSO. The subsequent steps
were the same as those for the total ATP
determination. The 100 ml of the cells in DMSO
or cells in H20 was added to the 100 ml ATP assay
enzyme solution (containing luciferase, luciferin,
MgSO4, DTT, EDTA BSA and Tricine buffer
salt) (1:25 dilution of stock) and incubated.
Relative luminescence intensity (RLI) was deter-
mined instantly using a luminometer (Thermo
Labsystem, Franklin, MA). RLI data were con-
verted into ATP concentration using the ATP
standard curve constructed earlier. The intracellu-
lar ATP level was calculated by subtracting the
extracellular ATP level from the total ATP level.
Membrane potential (Dc) dissipation
The mid-log phase M. luteus culture was collected
by centrifugation and re-suspended in 50 mM
HEPES (pH 7.0). The cells were washed twice in
the buffer before they were re-suspended in the
buffer, which was ten times smaller in volume, to
achieve OD600=40. Fluorescence measurements
were performed in a PerkinElmer LS-50B spectro-
ﬂuorometer (PerkinElmer Life and Analytical
Sciences, Inc., Boston, MA). Parameters were set
up as: excitation=643 nm; emission=666 nm; and
slit width=10 nm for both. For each measure-
ment, 5 ml of 2 mM DiSC3 were added to a 2 ml
50 mM K-HEPES buffer (pH 7.0) to reach a ﬁnal
concentration of 5 mM. After stabilization of the
baseline, 20 ml cells were added (ﬁnal OD600 was
*0.3) followed by 20 ml 20% glucose to energize
the cells. Then 2 ml of 5 mM nigericin (ﬁnal
concentration of 5 mM) were added to convert
the pH gradient. Different amounts of either nisin
or lactocin were used to deplete Dc after signal
stabilization. Finally, 20 ml 0.3 mM valinomycin
(ﬁnal concentration of 3 mM) were added to
observe complete dissipation of the Dc.T h e
increase in the ﬂuorescence intensity induced by
different bacteriocins or different concentrations of
the same bacteriocin was compared. Fluorescence
intensity after the addition of nigericin was denoted
as I0. Intensity following the addition of any
bacteriocin was denoted as It and intensity after
valinomycin-induced total depletion of membrane
potential was I?. Therefore, the Dc dissipation
percentage (%) can be calculated as
Dc dissipation %=(It -I 0 )/ (I? -I 0 ) 6 100
Statistical analysis
The variance of the data between the replicates was
less than 10%. Standard deviation was calculated for
each cell population studied.
Results
Using the method developed in our laboratory, we
isolated the antibacterial peptide with the molecu-
lar weight of 3.8 kDa (Figure 1). According to the
SDS-PAGE, lactocin 160 was the only protein
present in the preparation. However in addition to
the peptide, the lactocin 160 partially puriﬁed
preparation contained CDM components and
possibly metabolic products of a non-proteinaceous
nature.
The minimum inhibitory concentration (MIC) of
the lactocin 160 partially puriﬁed preparation
against M. luteus ATCC 10420 was 5 mg/ml.
CDM had no effect on the growth of the tested
microorganism.
There were no signiﬁcant changes in the intracel-
lular ATP level of M. luteus upon the addition of
20 mg/ml of lactocin 160 (partially puriﬁed prepara-
tion of 20 mg/ml of total sample, data not shown). At
the same time, the extracellular ATP level increased
Figure 1. Lactocin 160, MW*3.8 kDa.
Lactocin 160 inhibits Micrococcus luteus 137signiﬁcantly (Figure 2). This means that treatment of
the cells with lactocin 160 resulted in an efﬂux of
ATP from inside of the cells.
As shown in Table I, 8.0 mg/ml of partially
puriﬁed lactocin 160 preparation (16 mg /ml of the
bacteriocin in the sample) dissipated 3.12+0.36%
of Dc.
Discussion
Bacteriocins exhibit inhibitory effects against var-
ious pathogens in a manner similar to antibiotics.
However, bacteriocins are distinguished from anti-
biotics on the basis of their synthesis, mode of
action, toxicity and resistance mechanisms [15,16].
Organisms resistant to antibiotics are generally not
cross-resistant with bacteriocins, and bacteriocin
resistance is not always genetically determined
[17].
Bacteriocins kill sensitive cells by depleting the
transmembrane potential (Dc) and/or the pH
gradient and forming pores in the membrane,
resulting in the leakage of cellular materials [18].
Electrostatic interactions with negatively charged
phosphate groups on target cell membranes con-
tribute to the initial binding of many bacteriocins
to the sensitive cell’s membrane [19,20]. Other
factors, such as the phospholipid composition of
the target bacterial membrane and the environ-
mental pH, inﬂuence the bacteriocin’s activity [19].
In this study we elucidated the general mechan-
ism of action of partially puriﬁed lactocin 160 from
vaginal L. rhamnosus against M. luteus ATCC
10420. We intentionally studied the peptide in its
partially puriﬁed form, which contains a trace of
media components. Lactocin 160 is normally
secreted from the strain into the vaginal environ-
ment. We speculate that the CDM, which mimics
vaginal ﬂuid, may also stabilize and protect the
peptide from degradation. Therefore, it should be
present in lactocin 160 topical vaginal microbicide
formulation.
It was shown that lactocin 160 disturbs the
cellular membrane and induces ATP efﬂux. Bac-
teriocins are known to deplete intracellular ATP as
a result of pore formation [17]. Dissipation of Dc
is a typical characteristic of the pore-forming
bacteriocin as it indicates the disturbance of the
membrane’s integrity by the bacteriocin molecules.
In this study, we found that lactocin 160 dissipates
the membrane potential of sensitive cells. Thus,
dissipation of membrane potential is only part of
the mode of action of lactocin 160. In addition,
lactocin 160 did not affect the membrane pH
gradient (DpH) of M. luteus (data not shown). This
was not a surprise since some bacteriocins selec-
tively dissipate one component of the proton
motive force. Bacteriocins, such as lactococcin G
and lactocin 3147 were reported to induce pores
selective for K
+ ions and inorganic phosphate [21–
24]. Enterocin P caused a signiﬁcant reduction of
membrane potential (Dc) and the intracellular pool
of ATP from Enterococcus faecium T136. However,
the DpH was not affected in the cells of E. faecium
treated with enterocin P [21]. Therefore in
addition to the membrane potential dissipation,
there must be some other mechanism(s) that
contribute(s) to the antimicrobial action of lactocin
160 observed in the well-diffusion assay.
Using the commonly accepted method for
testing bacteriocin activity, with M. luteus ATCC
10420 as the test strain, we showed that a partially
puriﬁed preparation of lactocin 160 has a mode of
action typical for bacteriocins. The antimicrobial
activity of this partially puriﬁed lactocin 160
preparation was somewhat low for M. luteus ATCC
10420. This is because this preparation is likely to
contain media components of a non-proteinaceous
nature and metabolic products that were not
removed by the partial puriﬁcation. Therefore we
Table I. Dissipation of Dc in M. luteus ATCC 10420 by lactocin
160.
Amount of partially puriﬁed lactocin 160 preparation








Figure 2. Inﬂuence of lactocin 160 on extracellular ATP levels in
M. luteus ATCC 10420. The changes in extracellular ATP level
induced by lactocin 160 (open circles) were compared with ATP
level in non-treated cells (closed circles).
138 J. Li et al.assume that the lactocin 160, puriﬁed to homo-
geneity, will have a much higher activity suitable
for application. However, the goal of this research
was not to purify lactocin 160 to homogeneity but
to obtain, for the ﬁrst time, preliminary data on the
possible mechanism of action of lactocin 160
isolated from a vaginal specimen dominated by
Lactobacillus. The preliminary mode of action study
was performed using the strain of M. luteus that is
commonly accepted as a reference bacteriocin-
sensitive organism. However, it is not the most
lactocin 160-sensitive strain and it is not a vaginal
isolate. In fact, vaginal pathogens are more
sensitive to lactocin 160 than M. luteus (personal
communication). In addition commercially avail-
able topical antimicrobials, such as 2% cleocin and
0.75% metrogel that are usually prescribed for the
treatment of bacterial vaginosis and other vaginitis,
release 100 mg of clindamycin (single dose) and
37.5 mg of metronidazole. These very high con-
centrations of antimicrobials kill not only BV-
associated bacteria but also healthy vaginal lacto-
bacilli [25,26]. At the same time, our partially
puriﬁed preparation of lactocin 160 kills BV-
associated microorganisms but does not kill healthy
vaginal microﬂora, therefore it is speciﬁc in its
antimicrobial action (personal communication).
The rapidly increasing prevalence of genital
pathogens resistant to conventional antibiotics has
prompted a search for new therapeutic agents. An
antibacterial peptide produced by vaginal lactobacilli
and having a mechanism of action different from
conventional antibiotics can be a good choice for the
replacement of antibiotics in the prophylaxis of BV.
Further study of lactocin 160s mechanism of action
will be performed using G. vaginalis as a major BV-
associated microorganism and puriﬁed to homoge-
neity preparation of the bacteriocin.
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